TASSO (Osimertinib) 80mg*30 | Julphar Bangladesh Generic | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: TASSO (Osimertinib) 80mg — Bangladesh

TASSO is a Bangladeshi generic of osimertinib, manufactured by Jenphar Bangladesh Ltd., the Bangladesh affiliate of the Julphar (Gulf Pharmaceutical Industries) group. Supplied as 80 mg film-coated tablets in a 30-tablet pack, TASSO matches the originator's standard once-daily strength. Julphar is a large, internationally certified pharmaceutical group headquartered in the UAE with manufacturing facilities in several countries, including Bangladesh, where TASSO is produced and registered for the local market.

The name "TASSO" appears in Bangladeshi drug indices as an osimertinib 80 mg brand, and "Jenphar Bangladesh" is the manufacturing entity. Buyers should recognise both names when verifying a batch, with osimertinib as the critical active-ingredient marker.

What Is TASSO Used For?

TASSO treats EGFR mutation-positive non-small cell lung cancer, including first-line advanced disease, T790M-positive disease after resistance to a prior EGFR TKI, and adjuvant therapy after surgery in eligible EGFR-mutant patients. Its blood-brain barrier penetration also supports use when central nervous system metastases are present.

How Does TASSO Work?

Osimertinib, the active ingredient in TASSO, is an irreversible mutant-selective EGFR inhibitor. It blocks EGFR bearing exon 19 deletions, L858R mutations and the T790M mutation while sparing wild-type EGFR, which explains both its multi-line efficacy and its relatively manageable rash and diarrhoea.

Indications

  • First-line advanced EGFR-mutant NSCLC.
  • Adjuvant therapy after resection of EGFR-mutant NSCLC.
  • T790M-positive NSCLC after prior EGFR-TKI therapy.

Dosage and Administration

TASSO is taken as one 80 mg tablet once daily, with or without food, swallowed whole. Missed doses beyond 12 hours are skipped. The dose may be reduced to 40 mg daily to manage side effects, and therapy continues until progression or unacceptable toxicity.

Side Effects

Common side effects include diarrhoea, rash, dry skin, nail changes, stomatitis and fatigue. Rare but serious events such as interstitial lung disease, QT prolongation and cardiomyopathy require monitoring; new respiratory symptoms or palpitations should be reported promptly.

Storage

Store TASSO below 30°C, in the original container, in a dry place, away from children. Do not use after the expiry date.

Why Choose the GLT?

GLT sources TASSO through verified channels and confirms the manufacturer (Jenphar Bangladesh / Julphar group) and batch details before shipping. Bangladeshi osimertinib generics typically cost several times less than branded Tagrisso in Western markets, making sustained targeted therapy more affordable. We offer clear documentation and direct support for both personal and institutional orders.

How to Order TASSO from GLT

Message GLT on WhatsApp at +86 15234153837 or email [email protected] to order TASSO 80 mg (30 tablets). Provide your quantity, destination country and order type, and we will confirm availability, batch documentation and shipping terms before dispatch.

FAQ

Who makes TASSO? TASSO is manufactured by Jenphar Bangladesh Ltd., part of the Julphar (Gulf Pharmaceutical Industries) group.

Is TASSO a generic of Tagrisso? Yes, TASSO contains the same active ingredient (osimertinib) at the same 80 mg dose.

Can I buy TASSO online? Yes, GLT can supply TASSO internationally; contact us on WhatsApp or email for availability.

Related Oncology Products

AVATODX (Avatrombopag) 20mg*30 Tablets | Bigbear Pharmaceutical Laos | GLT

AVATODX — avatrombopag 20mg by Bigbear Pharmaceutical (Lao) Co., Ltd., Lao Reg. 06L0985/23, 30-tablet bottle

XinKePing 欣可平 (Avatrombopag) 20mg*10 Tablets | Nanjing Hencer China | GLT

XinKePing — API-plus-tablet integrated avatrombopag from Nanjing Hencer Pharmaceutical (Jemcare group), China Mainland

Zepbound (Tirzepatide) 2.5–15mg/0.5mL Single-Dose Pen | Eli Lilly USA | GLT

Zepbound — Eli Lilly tirzepatide single-dose pen, six US strengths (2.5–15mg/0.5mL) for chronic weight management...

Baricent (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Incepta Pharmaceuticals Ltd. | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Incepta Pharmaceuticals Ltd. (Bangladesh) — an affordable alternative to Olumiant...

LuciAvat (Avatrombopag) 20mg*28 Tablets | Lucius Pharmaceuticals Laos | GLT

LuciAvat — avatrombopag 20mg (23.6mg maleate) film-coated tablets by Lucius Pharmaceuticals (Lao) Co., Ltd., Vientiane

KangQuXin 康曲欣 (Avatrombopag) 20mg*10 Tablets | Beijing Continent Gyre | GLT

KangQuXin — avatrombopag by Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), China Mainland

KeZeRui 科瑞泽 (Avatrombopag) 20mg*10 Tablets | Sichuan Kelun China | GLT

KeZeRui — national-procurement avatrombopag from Sichuan Kelun Pharmaceutical, China's integrated API + tablet maker

Eltrombopag (Promacta) 25mg/50mg Tablets | US Originator TPO-R Agonist | GLT

Novartis originator Promacta (eltrombopag) 25mg & 50mg, 30 tablets